This disconnect between tape measure results and scale readings is not a sign of failureit reflects how your body reshapes itself during GLP-1 therapy
Key medications your provider will flag include insulin and sulfonylureas (because combining them with GLP-1 medications increases the risk of hypoglycemia and doses may need adjustment), warfarin and other anticoagulants (because changes in absorption could affect clotting times), levothyroxine (because absorption may be delayed, though clinical significance is debated), oral contraceptives (because absorption timing may shift, though most providers consider this a low risk with modern formulations), and certain antibiotics and antiretroviral medications
District Court in New Jersey, contends Lilly's ads are "deliberately simple and deliberately false" because they tout "outdated clinical trials that compare the highest doses of the Lilly medicines to lower doses of Novo Nordisks medicines." Novo said the ads are deceptive because they present results as "proof of broad, product-level superiority while burying or omitting critical clinical context." John Kuckelman, Novo's senior vice president and group general counsel, said Lilly's ads have misled consumers
BPC-157 is intended strictly for laboratory research purposes only and is not approved for human or veterinary applications.
